Bioxytran (BIXT) Cash from Investing Activities Growth (1y) (2011 - 2026)
Bioxytran (BIXT) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -41.67% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -157.08% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -589.38% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -89.24% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 26.37% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 25.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61,413.33% |
| Dec 31, 2025 | 48.31% |
| Sep 30, 2025 | 84.53% |
| Jun 30, 2025 | -2,287.88% |
| Mar 31, 2025 | 99.75% |
| Dec 31, 2024 | -83.98% |
| Sep 30, 2024 | 14.75% |
| Jun 30, 2024 | 103.41% |
| Mar 31, 2024 | -27.26% |
| Dec 31, 2023 | -213.02% |
| Sep 30, 2023 | -64.57% |
| Jun 30, 2023 | -17,583.48% |
| Mar 31, 2023 | 78.90% |
| Dec 31, 2022 | 92.51% |
| Jun 30, 2022 | -11,400.00% |
| Mar 31, 2022 | -149.34% |
| Dec 31, 2013 | 100.02% |
| Sep 30, 2013 | -163.16% |
| Dec 31, 2012 | -51.03% |
| Sep 30, 2012 | 137.35% |